Replies to post #2019 on Conatus Pharmaceuticals Inc. (CNAT)

[Lunacy_John Galt]

In the 8k. Placebo did significantly better than both treatment arms. This is a death blow I think. They didn’t even try to sugar coat or spin it. I can see NVS backing out now. I’m sorry for those that lost today.

[chainma1l]

From the 8k:

Item 8.01. Other Events.



On March 21, 2019, Conatus Pharmaceuticals Inc. (the “Company”) announced top-line results from the Company’s Phase 2b ENCORE-NF clinical trial of emricasan, the Company’s first-in-class, orally active pan-caspase inhibitor, in patients with biopsy-confirmed nonalcoholic steatohepatitis (“NASH”) and liver fibrosis. The randomized, double-blind trial, initiated in the first quarter of 2016, enrolled and treated 318 patients with biopsy-confirmed NASH Clinical Research Network (“CRN”) fibrosis stages F1-F3 at baseline. Patients were randomized 1:1:1 to receive 5 mg of emricasan, 50 mg of emricasan, or placebo twice daily for 72 weeks.

The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement with no worsening of steatohepatitis compared with placebo at week 72. The trial did not meet the primary endpoint. The response rates in the 5 mg emricasan, 50 mg emricasan and placebo treatment groups were 11.2%, 12.3% and 19.0%, respectively. Statistically significant reductions were observed in ALT and Caspase 3/7 in the 5 mg and 50 mg emricasan treatment groups.

Consistent with safety results from 18 previously completed clinical trials, emricasan was generally well-tolerated in the ENCORE-NF clinical trial.